Drug Interactions and Polypharmacy in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss the importance of evaluating drug drug interaction profiles when selecting androgen receptor pathway inhibitors for patients with metastatic castration sensitive prostate cancer (mCSPC). Dr. Luz explains that many individuals with mCSPC are older and frequently take multiple medications for conditions such as cardiovascular disease, diabetes, and other chronic illnesses. As a result, clinicians must carefully assess potential interactions between cancer therapies and existing medications to avoid complications and ensure patient safety. The discussion highlights that certain therapies may interact with commonly prescribed drugs, which can influence treatment choice and monitoring strategies. Dr. Luz also emphasizes the importance of multidisciplinary collaboration with primary care physicians, cardiologists, and other specialists when managing complex patients. This segment underscores how careful review of polypharmacy and drug interaction risks plays a critical role in optimizing treatment selection for metastatic castration sensitive prostate cancer.